In Reply to 'Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations'.
(2022) Kidney medicine — Vol. 4, n° 8, p. 100503 (2022)
Files
2022_Fernandez_Kidney_Med.pdf
Open Access - Adobe PDF
- 181.17 KB
Details
- Authors
- Abstract
- We thank Mungmunpuntipantip and Wiwanitkit1 for their constructive comments. Among the 47 kidney transplant recipients included in this study, 17 had antihuman leukocyte antigen antibodies detected within 2 years prior to infection, but none had donor-specific antibodies.2 Antihuman leukocyte antigen antibody status was not available for 6 patients. No patient was treated for acute rejection in the 2 years prior to infection. ^...]
- Affiliations
Citations
Fernandes, G., Devresse, A., Scohy, A., De Greef, J., Yombi, J. C., Belkhir, L., Darius, T., Mourad, M., Buemi, A., Kabamba-Mukadi, B., Goffin, E., & Kanaan, N. (2022). In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’. Kidney medicine, 4(8), 100503. https://doi.org/10.1016/j.xkme.2022.100503 (Original work published 2022)